BioSpace News Archive

The estimates of RNA expression at different times and the response of cells to environmental stimuli indirectly informing about broader biological events affecting a particular tissue in pathological or physiological conditions.

The growth of the global organoids and spheroids market is anticipated to be driven by the increased demand for tissue engineering and cell therapy.

The rising use of collagen in medical devices and drug delivery systems, increased preference for minimally invasive technologies, and the effectiveness in wound healing are expected to be some of the key factors driving the global demand for collagen in the coming years.

Transgene announced that detailed results of the data from the Phase 1b/2 trial combining TG4001, a HPV16 targeted therapeutic vaccine, with avelumab, a human anti-PD-L1 antibody, in HPV16-positive recurrent and/or metastatic malignancies, will be presented in a poster presentation at the upcoming virtual meeting of the Society for Immunotherapy of Cancer taking place November 9-14, 2020.

Akron Biotechnology announced it has signed an agreement with Synairgen plc for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta therapeutic candidate for the treatment of COVID-19 patients.

Calliditas Therapeutics AB announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology Kidney Week 2020 Reimagined conference, to be held virtually October 19-25, 2020.

Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce encouraging headline results from a Phase I study at the University of California, San Francisco in patients with Diffuse Intrinsic Pontine Glioma .

Oncopeptides AB announces that the Company has submitted an Investigational New Drug application to the U.S. Food and Drug Administration, for OPD5 - a second drug candidate based on the proprietary Peptide Drug Conjugate platform.

XPhyto Therapeutics Corp., a next-generation bioscience company, is pleased to announce an update on its third-party contract development programs.

OraSure Technologies, Inc. announced its DNA Genotek subsidiary has received Emergency Use Authorization from the U.S. Food and Drug Administration for the use of DNA Genotek’s OMNIgene®·ORAL saliva collection and stabilization device in COVID-19 testing.